-
DTC是最常见的内分泌系统肿瘤。目前,甲状腺球蛋白(thyroglobulin,Tg)和甲状腺球蛋白抗体(thyroglobulin antibody,TgAb)表达的检测、131I全身显像(whole body scan,WBS)以及颈部超声是DTC患者随访的重要方法[1-2]。131I-WBS包括诊断性全身显像(diagnostic whole body scan,Dx-WBS)和治疗性全身显像(post-treatment whole body scan,Rx-WBS)[3]。临床随访中部分患者会出现Tg表达呈阳性(简称Tg阳性)而131I-WBS结果呈阴性(简称131I-WBS阴性)的现象,18F-FDG PET/CT集功能显像和解剖显像于一体,对此类患者复发病灶的检出有重要价值[4-5]。高水平的TSH可能会刺激DTC细胞,从而产生更高的代谢需求,故18F-FDG PET/CT的诊断灵敏度可能更高[6]。但也有研究结果显示,不同TSH水平下18F-FDG PET/CT对DTC复发患者诊断灵敏度的差异并无统计学意义[7],且患者停服T4可能会导致医源性甲状腺功能减退,进而对患者的生活质量造成影响[8]。我们通过Meta分析评估18F-FDG PET/CT对Tg阳性且131I-WBS阴性的DTC复发患者的诊断效能,并分析比较不同TSH水平下行Dx-WBS与Rx-WBS的患者18F-FDG PET/CT诊断评价指标之间的差异,以期为此类患者的诊疗提供科学有效的依据和指导。
-
通过对数据库的检索共获得文献934篇,去除重复文献322篇,阅读文章题目、摘要和全文后初筛排除与主题不相关的文献588篇,根据纳入和排除标准复筛排除8篇,最终纳入16篇文献[10-25]进行Meta分析,16篇文献共1 036例DTC复发患者。纳入研究的基本特征和质量评价结果见表1。
研究者[文献] 发表年份 国家 研究
类型例数
(男/女)中位或平均年龄(岁) 肿瘤类型
(例数)TSH刺激 TSH水平
(IU/ml)Tg水平(ng/ml) 诊断“金标准” PET/CT厂家及型号 QUADAS-2量表评分(分) Esteva等[10] 2009 西班牙 回顾性 50(11/39) 39.4 P(38),F(12) 是 E:>55 E:105.8(1~568) 病理、随访 西门子 ECAT EXACT 47 12 Giovanella等[11] 2012 瑞士 前瞻性 42(−) − − 否 − RP:9.4(1.6~104.6)
RN:3.0(1.0~7.2)病理、随访 西门子Biograph 6 9 Vural等[12] 2012 土耳其 前瞻性 105(38/67) 51.7 − 是 − E:166.5±507.4 病理、随访 西门子Biograph 6 9 Kunawudhi等[13] 2012 泰国 前瞻性 30(8/22) 52 P(25),F(1),
B(4)否 − 均值12.56 病理、随访 西门子Biograph 16 11 Ozkan等[14] 2013 土耳其 回顾性 49(−) − P(49) 是/否 E:>30
S:−E:93.8±124.5 病理 GE Discovery STE 7 Giovanella等[15] 2013 瑞士 回顾性 102(−) − − 否 S:0.2(0.01~0.2) PP:6.7(0.7~73.6)
PN:1.8(0.5~4.9)病理、随访 西门子Biograph 6 11 Kundu等[16] 2014 印度 前瞻性 62(25/37) 42.5 P(56),F(6) 是 E:>30 275±480.7 病理、随访 西门子Biograph 2 14 胡斌等[17] 2015 中国 回顾性 32(11/21) 50.5 P(25),F(7) 是 E:≥30 PP:32.6
PN:19.3病理、随访 飞利浦 GEMINITF-128 14 Ma等[18] 2015 中国 回顾性 41(11/30) 42±12.6 P(40),F(1) 是 − 20.6(10.6~1 600) 病理、随访 西门子Biograph mCT 12 Elboga等[19] 2015 土耳其 回顾性 90(31/59) 44.1 P(82),F(8) 否 S:<2 − 随访 − 13 Choi等[20] 2016 韩国 回顾性 75(21/54) 47.4 P(74),F(1) 是/否 E:≥30.5
S:−40.3(2.1~496.2) 病理、随访 GE Discovery STE 11 薛明媚等[21] 2016 中国 回顾性 33(10/23) 44.4 P(31),F(2) 是 E:>30 − 病理、随访 西门子 Biograph True
Point 6411 程旭等[22] 2018 中国 回顾性 72(31/41) 43.9 P(18),F(14) 是 E:>30 PP:224.19±265.12 病理、随访 西门子Biograph 16 10 Piccardo等[23] 2019 意大利 前瞻性 25(7/18) 62 P(18),F(7) 否 S:<0.2 6.9(5.1~11.27) 病理、随访 − 9 Albano等[24] 2021 意大利 回顾性 113(52/61) 54 P(71),F(19),H(7),O(16) 是 E:>30 PP:156±133
PN:18±15病理、随访 GE Discovery STE 12 Almeida等[25] 2020 巴西 前瞻性 15(3/12) 55.7 − 是/否 E:129.8±77.6
S:0.4±0.6S:892.9±1 652.3
E:1 226.1±1 783病理、随访 西门子 Biograph mCT 12 注:病理为组织病理学检查;随访包括影像学、生化检查。Tg为甲状腺球蛋白;WBS为全身显像;DTC为分化型甲状腺癌;FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;TSH为促甲状腺激素;QUADAS为诊断试验质量评价工具;P为甲状腺乳头状癌;F为甲状腺滤泡状癌;B为甲状腺乳头状癌合并滤泡状癌;H为甲状腺嗜酸性细胞肿瘤;O为甲状腺癌其他亚型;E为刺激状态;S为抑制状态;RP为参考标准下阳性;RN为参考标准下阴性;PP为PET/CT显像阳性;PN为PET/CT显像阴性。−表示无此项数据 表 1 16篇Tg阳性且131I-WBS阴性的DTC复发患者18F-FDG PET/CT诊断效能研究的基本特征及质量评价
Table 1. Basic characteristics and quality evaluation of the 16 included studies of 18F-FDG PET/CT in diagnosis of thyroglobulin-positive and 131I whole body imaging-negative differentiated thyroid cancer recurrence patients
-
Tg阳性且131I-WBS阴性的DTC复发患者通过18F-FDG PET/CT诊断的r=−0.035,P=0.896,这表明不存在阈值效应;18F-FDG PET/CT以DOR为效应量计算(I2=47.5%,P=0.018),采用随机效应模型进行合并。18F-FDG PET/CT诊断Tg阳性且131I-WBS阴性的DTC复发患者的合并灵敏度为0.87(95%CI:0.82~0.91)、特异度为0.79(95%CI:0.68~0.86)、PLR=3.76(95%CI:2.32~6.09)、NLR=0.20(95%CI:0.14~0.27)、DOR=23.89(95%CI:13.23~43.12)、SROC的AUC=0.91(标准误0.02)、Q指数为0.837(标准误0.023)。其他具体数据见图1、2。
-
Meta回归分析结果显示,异质性可能源于病例数(r=1.462,P=0.021,相对DOR=4.32)(表2)。
影响因素 相关
系数标准误 相对
DORP值 患者人种(亚裔人对高加索人) 0.462 0.688 1.59 0.513 研究类型(前瞻性对回顾性) −0.893 0.724 0.41 0.239 PET/CT厂家(西门子对GE) −0.800 0.712 0.45 0.286 病例数(<50对≥50) 1.462 0.556 4.32 0.021 TSH刺激(是对否) −0.663 0.656 0.52 0.336 131I-WBS(诊断性对治疗性) 0.306 0.752 1.36 0.691 文献发表年份(2015年前对
2015年及以后)0.738 0.644 2.09 0.272 注:Tg为甲状腺球蛋白;WBS为全身显像;DTC为分化型甲状腺癌;FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;DOR为诊断优势比;TSH为促甲状腺激素 表 2 16篇Tg阳性且131I-WBS阴性的DTC复发患者18F-FDG PET/CT诊断效能研究的Meta回归分析结果
Table 2. Meta regression analysis results of the 16 included studies of 18F-FDG PET/CT in diagnosis of thyroglobulin-positive and 131I whole body imaging-negative differentiated thyroid cancer recurrence patients
-
改变效应模型后,汇总的灵敏度、特异度和DOR无明显变化,这表明Meta分析结果较为稳定。Deeks线性回归分析结果显示,各纳入研究之间存在较小的发表偏倚(P=0.070,图3)。
-
由图4可见,行Dx-WBS患者的18F-FDG PET/CT的合并灵敏度为0.87(95%CI:0.75~0.94)、特异度为0.82(95%CI:0.65~0.92)、PLR=4.40(95%CI:1.68~11.53)、NLR=0.23(95%CI:0.15~0.35)、DOR=−26.68(95%CI:12.47~57.08)、SROC的AUC=0.91(标准误0.03)、Q指数为0.837(标准误0.029)。由图5可见,行Rx-WBS患者的18F-FDG PET/CT的合并灵敏度为0.90(95%CI:0.85~0.94)、特异度为0.76(95%CI:0.66~0.84)、PLR=3.39(95%CI:2.00~5.75)、NLR=0.16(95%CI:0.09~0.26)、DOR=24.64(95%CI:10.20~59.51)、SROC的AUC=0.91(标准误0.06)、Q指数为0.840(标准误0.066)。2种显像方法的Q指数的差异无统计学意义(Z=0.041,P=0.970)。
图 4 行诊断性全身显像患者18F-FDG PET/CT诊断DTC复发的合并灵敏度、特异度森林图(A)及综合受试者工作特征曲线(B) ⑩~㉕表示参考文献的序号。 FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;DTC为分化型甲状腺癌;AUC为曲线下面积;df为自由度;CI 为置信区间
Figure 4. Forest plot of combined sensitivity, specificity (A) and summary receiver operator characteristic curve (B) of 18F-FDG PET/CT in diagnosis of patients with differentiated thyroid cancer recurrence undergoing diagnostic whole body scan
图 5 行治疗性全身显像患者18F-FDG PET/CT诊断DTC复发的合并灵敏度、特异度森林图(A)及综合受试者工作特征曲线(B) ⑩~㉕表示参考文献的序号。FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;DTC为分化型甲状腺癌;AUC为曲线下面积;df为自由度;CI 为置信区间
Figure 5. Forest plot of combined sensitivity, specificity (A) and summary receiver operator characteristic curve (B) of 18F-FDG PET/CT in diagnosis of patients with differentiated thyroid cancer recurrence undergoing Rx-WBS
-
行Dx-WBS患者在TSH刺激状态下18F-FDG PET/CT的合并灵敏度为0.79(95%CI:0.71~0.85)、特异度为0.87(95%CI:0.77~0.94)、PLR=5.00(95%CI:2.83~8.81)、NLR=0.28(95%CI:0.20~0.40)、DOR=18.46(95%CI:8.59~39.69)、SROC的AUC=0.864(标准误0.039)、Q指数为0.795(标准误0.038)、在TSH抑制状态下18F-FDG PET/CT的合并灵敏度为0.90(95%CI:0.82~0.95)、特异度为0.83(95%CI:0.72~0.90)、PLR=4.39(95%CI:2.79~6.91)、NLR=0.15(95%CI:0.09~0.26)、DOR=55.66(95%CI:19.23~161.2)、SROC的AUC=0.944(标准误0.022)、Q指数为0.883(标准误0.028)。行Dx-WBS的患者2种TSH状态下的Q指数的差异无统计学意义(Z=1.864,P=0.062)。
行Rx-WBS的患者在TSH刺激状态下18F-FDG PET/CT的合并灵敏度为0.90(95%CI:0.86~0.94)、特异度为0.77(95%CI:0.68~0.84)、PLR=3.01(95%CI:1.28~7.07)、NLR=0.15(95%CI:0.08~0.28)、DOR=24.42(95%CI:8.44~70.67)、SROC的AUC=0.935(标准误0.049)、Q指数为0.871(标准误0.060);在TSH抑制状态下18F-FDG PET/CT的合并灵敏度为0.88(95%CI:0.85~0.94)、特异度为0.76(95%CI:0.66~0.84)、PLR=3.17(95%CI:1.54~6.54)、NLR=0.20(95%CI:0.09~0.44)、DOR=21.87(95%CI:5.25~91.06)、SROC的AUC=0.871(标准误0.121)、Q指数为0.801(标准误0.119)。行Rx-WBS的患者2种TSH状态下的Q指数的差异无统计学意义(Z=0.525,P=0.596)。
18F-FDG PET/CT对Tg阳性且131I-WBS阴性的DTC复发患者的诊断效能:Meta分析
Diagnostic efficacy of 18F-FDG PET/CT in thyroglobulin-positive and 131I whole body imaging-negative differentiated thyroid cancer recurrence patients: a meta-analysis
-
摘要:
目的 系统评价18F-氟脱氧葡萄糖(FDG)PET/CT对甲状腺球蛋白(Tg)表达阳性(简称Tg阳性)且131I全身显像(WBS)结果阴性(简称131I-WBS阴性)的分化型甲状腺癌(DTC)复发患者的诊断效能。 方法 检索PubMed、Embase、Cochrane Library和万方数据知识服务平台、中国知网、维普数据库、中国生物医学文献数据库中关于18F-FDG PET/CT对DTC复发患者诊断的相关研究,检索时间从建库至2020年12月。根据纳入和排除标准筛选文献,提取研究的基本特征和诊断参数,采用Spearman相关系数分析文献是否存在阈值效应,对纳入文献进行异质性Q检验,采用Deeks线性回归分析法评价文献的发表偏倚。绘制综合受试者工作特征(SROC)曲线,计算曲线下面积(AUC),采用Z检验分析行诊断性全身显像(Dx-WBS)与治疗性全身显像(Rx-WBS)的患者18F-FDG PET/CT诊断效能的差异,并分析在促甲状腺激素(TSH)刺激状态与抑制状态下18F-FDG PET/CT诊断效能的差异。 结果 最终纳入16篇文献,共1 036例DTC复发患者,纳入研究的异质性较低(I2=47.5%,P=0.018),异质性可能源于病例数(r=1.462,P=0.021),存在较小的发表偏倚(P=0.070)。18F-FDG PET/CT诊断Tg阳性且131I-WBS阴性的DTC复发患者的合并灵敏度为0.87(95%CI:0.82~0.91)、特异度为0.79(95%CI:0.68~0.86)、阳性似然比为3.76(95%CI:2.32~6.09)、阴性似然比为0.20(95%CI:0.14~0.27)、诊断优势比为23.89(95%CI:13.23~43.12)、SROC的AUC=0.91(标准误0.02)、Q指数为0.837(标准误0.023)。行Dx-WBS与Rx-WBS的DTC复发患者18F-FDG PET/CT诊断效能的差异无统计学意义(Z=0.041,P>0.05)。在TSH刺激状态与抑制状态下,行Dx-WBS与Rx-WBS的DTC复发患者18F-FDG PET/CT诊断效能的差异均无统计学意义(Z=1.864、0.525,均P>0.05)。 结论 18F-FDG PET/CT对Tg阳性且131I-WBS阴性的DTC复发患者具有较高的诊断效能,行Dx-WBS与Rx-WBS、在TSH刺激状态与抑制状态下患者18F-FDG PET/CT的诊断效能均相当。 -
关键词:
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 分化型甲状腺癌 /
- 甲状腺球蛋白 /
- 131I全身显像 /
- Meta分析
Abstract:Objective To systematically evaluate the diagnostic efficacy of 18F-fluorodeoxyglucose (FDG) PET/CT in differentiated thyroid cancer (DTC) recurrence patients with positive expression for thyroglobulin (Tg) (referred as Tg-positive) and negative result for 131I whole body imaging (WBS) (referred as 131I-WBS-negative). Methods PubMed, Embase, Cochrane Library, Wanfang Data Knowledge Service Platform, China National Knowledge Internet, VIP Database, and China Biomedical Literature Database were searched for relevant studies on the diagnosis of DTC recurrence by 18F-FDG PET/CT. The search time was from database establishment to December 2020. The literature was screened according to the inclusion and exclusion criteria, the basic characteristics and diagnostic parameters of the studies were extracted. Spearman correlation coefficient was used to analyze whether there was a threshold effect in the literature. Heterogeneity Q test was performed for the included literature, and Deeks linear regression analysis was used to evaluate the publication bias of the literature. The summary receiver operetor characteristic (SROC) curve was drawn, the area under the curve (AUC) was calculated, and the Z test was used to analyze the difference in the diagnostic performance of 18F-FDG in patients undergoing diagnostic whole-body imaging (Dx-WBS) and therapeutic imaging (Rx-WBS). The differences in the diagnostic performance of 18F-FDG PET/CT between thyroid-stimulating hormone (TSH)-stimulated and suppressed states were also analyzed. Results Finally, 16 articles were included, with a total of 1 036 patients with DTC recurrence. The heterogeneity of the included studies was low (I2=47.5%, P=0.018), which may be due to the number of cases (r=1.462, P=0.021), and there was a small publication bias (P=0.070). The combined sensitivity of 18F-FDG PET/CT in diagnosing Tg-positive and 131I-WBS-negative DTC recurrence patients was 0.87(95%CI: 0.82−0.91), the specificity was 0.79(95%CI: 0.68−0.86), and the positive likelihood ratio was 3.76(95%CI: 2.32−6.09), the negative likelihood ratio was 0.20(95%CI: 0.14−0.27), the diagnostic odds ratio was 23.89(95%CI: 13.23−43.12), and the AUC of SROC=0.905 (standard error of 0.022) and Q-index was 0.837 (standard error of 0.023). There was no significant difference in the diagnostic performance of 18F-FDG PET/CT between patients undergoing Dx-WBS and Rx-WBS (Z=0.041, P>0.05); there was no significant difference in the diagnostic performance of 18F-FDG PET/CT between TSH-stimulated and suppressed states undergoing Dx-WBS and Rx-WBS (Z=1.864, 0.525; both P>0.05). Conclusions 18F-FDG PET/CT has high diagnostic efficacy for Tg-positive and 131I-WBS-negative DTC recurrence patients. The diagnostic efficacy of 18F-FDG PET/CT in patients undergoing Dx-WBS and Rx-WBS, in TSH-stimulated and suppressed states is similar. -
图 4 行诊断性全身显像患者18F-FDG PET/CT诊断DTC复发的合并灵敏度、特异度森林图(A)及综合受试者工作特征曲线(B) ⑩~㉕表示参考文献的序号。 FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;DTC为分化型甲状腺癌;AUC为曲线下面积;df为自由度;CI 为置信区间
Figure 4. Forest plot of combined sensitivity, specificity (A) and summary receiver operator characteristic curve (B) of 18F-FDG PET/CT in diagnosis of patients with differentiated thyroid cancer recurrence undergoing diagnostic whole body scan
图 5 行治疗性全身显像患者18F-FDG PET/CT诊断DTC复发的合并灵敏度、特异度森林图(A)及综合受试者工作特征曲线(B) ⑩~㉕表示参考文献的序号。FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;DTC为分化型甲状腺癌;AUC为曲线下面积;df为自由度;CI 为置信区间
Figure 5. Forest plot of combined sensitivity, specificity (A) and summary receiver operator characteristic curve (B) of 18F-FDG PET/CT in diagnosis of patients with differentiated thyroid cancer recurrence undergoing Rx-WBS
表 1 16篇Tg阳性且131I-WBS阴性的DTC复发患者18F-FDG PET/CT诊断效能研究的基本特征及质量评价
Table 1. Basic characteristics and quality evaluation of the 16 included studies of 18F-FDG PET/CT in diagnosis of thyroglobulin-positive and 131I whole body imaging-negative differentiated thyroid cancer recurrence patients
研究者[文献] 发表年份 国家 研究
类型例数
(男/女)中位或平均年龄(岁) 肿瘤类型
(例数)TSH刺激 TSH水平
(IU/ml)Tg水平(ng/ml) 诊断“金标准” PET/CT厂家及型号 QUADAS-2量表评分(分) Esteva等[10] 2009 西班牙 回顾性 50(11/39) 39.4 P(38),F(12) 是 E:>55 E:105.8(1~568) 病理、随访 西门子 ECAT EXACT 47 12 Giovanella等[11] 2012 瑞士 前瞻性 42(−) − − 否 − RP:9.4(1.6~104.6)
RN:3.0(1.0~7.2)病理、随访 西门子Biograph 6 9 Vural等[12] 2012 土耳其 前瞻性 105(38/67) 51.7 − 是 − E:166.5±507.4 病理、随访 西门子Biograph 6 9 Kunawudhi等[13] 2012 泰国 前瞻性 30(8/22) 52 P(25),F(1),
B(4)否 − 均值12.56 病理、随访 西门子Biograph 16 11 Ozkan等[14] 2013 土耳其 回顾性 49(−) − P(49) 是/否 E:>30
S:−E:93.8±124.5 病理 GE Discovery STE 7 Giovanella等[15] 2013 瑞士 回顾性 102(−) − − 否 S:0.2(0.01~0.2) PP:6.7(0.7~73.6)
PN:1.8(0.5~4.9)病理、随访 西门子Biograph 6 11 Kundu等[16] 2014 印度 前瞻性 62(25/37) 42.5 P(56),F(6) 是 E:>30 275±480.7 病理、随访 西门子Biograph 2 14 胡斌等[17] 2015 中国 回顾性 32(11/21) 50.5 P(25),F(7) 是 E:≥30 PP:32.6
PN:19.3病理、随访 飞利浦 GEMINITF-128 14 Ma等[18] 2015 中国 回顾性 41(11/30) 42±12.6 P(40),F(1) 是 − 20.6(10.6~1 600) 病理、随访 西门子Biograph mCT 12 Elboga等[19] 2015 土耳其 回顾性 90(31/59) 44.1 P(82),F(8) 否 S:<2 − 随访 − 13 Choi等[20] 2016 韩国 回顾性 75(21/54) 47.4 P(74),F(1) 是/否 E:≥30.5
S:−40.3(2.1~496.2) 病理、随访 GE Discovery STE 11 薛明媚等[21] 2016 中国 回顾性 33(10/23) 44.4 P(31),F(2) 是 E:>30 − 病理、随访 西门子 Biograph True
Point 6411 程旭等[22] 2018 中国 回顾性 72(31/41) 43.9 P(18),F(14) 是 E:>30 PP:224.19±265.12 病理、随访 西门子Biograph 16 10 Piccardo等[23] 2019 意大利 前瞻性 25(7/18) 62 P(18),F(7) 否 S:<0.2 6.9(5.1~11.27) 病理、随访 − 9 Albano等[24] 2021 意大利 回顾性 113(52/61) 54 P(71),F(19),H(7),O(16) 是 E:>30 PP:156±133
PN:18±15病理、随访 GE Discovery STE 12 Almeida等[25] 2020 巴西 前瞻性 15(3/12) 55.7 − 是/否 E:129.8±77.6
S:0.4±0.6S:892.9±1 652.3
E:1 226.1±1 783病理、随访 西门子 Biograph mCT 12 注:病理为组织病理学检查;随访包括影像学、生化检查。Tg为甲状腺球蛋白;WBS为全身显像;DTC为分化型甲状腺癌;FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;TSH为促甲状腺激素;QUADAS为诊断试验质量评价工具;P为甲状腺乳头状癌;F为甲状腺滤泡状癌;B为甲状腺乳头状癌合并滤泡状癌;H为甲状腺嗜酸性细胞肿瘤;O为甲状腺癌其他亚型;E为刺激状态;S为抑制状态;RP为参考标准下阳性;RN为参考标准下阴性;PP为PET/CT显像阳性;PN为PET/CT显像阴性。−表示无此项数据 表 2 16篇Tg阳性且131I-WBS阴性的DTC复发患者18F-FDG PET/CT诊断效能研究的Meta回归分析结果
Table 2. Meta regression analysis results of the 16 included studies of 18F-FDG PET/CT in diagnosis of thyroglobulin-positive and 131I whole body imaging-negative differentiated thyroid cancer recurrence patients
影响因素 相关
系数标准误 相对
DORP值 患者人种(亚裔人对高加索人) 0.462 0.688 1.59 0.513 研究类型(前瞻性对回顾性) −0.893 0.724 0.41 0.239 PET/CT厂家(西门子对GE) −0.800 0.712 0.45 0.286 病例数(<50对≥50) 1.462 0.556 4.32 0.021 TSH刺激(是对否) −0.663 0.656 0.52 0.336 131I-WBS(诊断性对治疗性) 0.306 0.752 1.36 0.691 文献发表年份(2015年前对
2015年及以后)0.738 0.644 2.09 0.272 注:Tg为甲状腺球蛋白;WBS为全身显像;DTC为分化型甲状腺癌;FDG为氟脱氧葡萄糖;PET为正电子发射断层显像术;CT为计算机体层摄影术;DOR为诊断优势比;TSH为促甲状腺激素 -
[1] 中国临床肿瘤学会(CSCO)甲状腺癌专家委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医师协会外科医师分会甲状腺外科医师委员会, 等. 碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019, 29(6): 476−480. DOI: 10.19401/j.cnki.1007-3639.2019.06.013.
Chinese Society of Clinical Oncology (CSCO) Thyroid Cancer Expert Committee, Chinese Research Hospital Association Thyroid Disease Committee, Chinese Thyroid Association, Chinese Collage of Surgeons, Chinese Medical Doctor Association, et al. Consensus on the diagnosis and management of iodine-refractory differentiated thyroid cancer (2019 edition)[J]. China Oncol, 2019, 29(6): 476−480. DOI: 10.19401/j.cnki.1007-3639.2019.06.013.[2] Shangguan LJ, Fang SW, Zhang PP, et al. Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy[J]. Ann Nucl Med, 2019, 33(3): 177−183. DOI: 10.1007/s12149-018-01321-w. [3] 李慧. 核医学分子影像在分化型甲状腺癌中的应用现状与进展[J]. 中国癌症杂志, 2018, 28(7): 481−486. DOI: 10.19401/j.cnki.1007-3639.2018.07.001.
Li H. Molecular imaging of nuclear medicine in differentiated thyroid cancer: current status and future direction[J]. China Oncol, 2018, 28(7): 481−486. DOI: 10.19401/j.cnki.1007-3639.2018.07.001.[4] Manohar PM, Beesley LJ, Bellile EL, et al. Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer[J]. Clin Nucl Med, 2018, 43(9): 641−647. DOI: 10.1097/RLU.0000000000002193. [5] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会. 分化型甲状腺癌术后管理中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(9): 1021−1028. DOI: 10.19538/j.cjps.issn1005-2208.2020.09.04.
Chinese Thyroid Association, Chinese Collage of Surgeons, Chinese Medical Doctor Association, Chinese Research Hospital Association Thyroid Disease Committee. Expert consensus on postoperative management of differentiated thyroid cancer (2020 edition)[J]. Chin J Pract Surg, 2020, 40(9): 1021−1028. DOI: 10.19538/j.cjps.issn1005-2208.2020.09.04.[6] Larg MI, Barbus E, Gabora K, et al. 18F-FDG PET/CT in differentiated thyroid carcinoma[J]. Acta Endocrinol (Buchar), 2019, 15(2): 203−208. DOI: 10.4183/aeb.2019.203. [7] Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2009, 94(4): 1310−1316. DOI: 10.1210/jc.2008-1747. [8] Leenhardt L, Leboulleux S, Bournaud C, et al. Recombinant thyrotropin vs levothyroxine withdrawal in 131I therapy of N1 thyroid cancer: a large matched cohort study (ThyrNod)[J]. J Clin Endocrinol Metab, 2019, 104(4): 1020−1028. DOI: 10.1210/jc.2018-01589. [9] Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8): 529−536. DOI: 10.7326/0003-4819-155-8-201110180-00009. [10] Esteva D, Muros MA, Llamas-Elvira JM, et al. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer[J]. Ann Surg Oncol, 2009, 16(7): 2006−2013. DOI: 10.1245/s10434-009-0483-8. [11] Giovanella L, Ceriani L, De Palma D, et al. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas[J]. Head Neck, 2012, 34(5): 626−631. DOI: 10.1002/hed.21791. [12] Vural GU, Akkas BE, Ercakmak N, et al. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data[J]. Clin Nucl Med, 2012, 37(10): 953−959. DOI: 10.1097/RLU.0b013e31825b2057. [13] Kunawudhi A, Pak-art R, Keelawat S, et al. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan[J]. Clin Nucl Med, 2012, 37(6): 561−567. DOI: 10.1097/RLU.0b013e318252d30e. [14] Ozkan E, Aras G, Kucuk NO. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results[J]. Clin Nucl Med, 2013, 38(5): 326−331. DOI: 10.1097/RLU.0b013e318286827b. [15] Giovanella L, Trimboli P, Verburg FA, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma[J]. Eur J Nucl Med Mol Imaging, 2013, 40(6): 874−880. DOI: 10.1007/s00259-013-2370-6. [16] Kundu P, Lata S, Sharma P, et al. Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT[J]. Eur J Nucl Med Mol Imaging, 2014, 41(7): 1354−1362. DOI: 10.1007/s00259-014-2723-9. [17] 胡斌, 王锦锋, 毛秋粉. 18F-FDGPET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J]. 国际放射医学核医学杂志, 2015, 39(3): 242−246, 251. DOI: 10.3760/cma.j.issn.1673-4114.2015.03.012.
Hu B, Wang JF, Mao QF. The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J]. Int J Radiat Med Nucl Med, 2015, 39(3): 242−246, 251. DOI: 10.3760/cma.j.issn.1673-4114.2015.03.012.[18] Ma C, Wang X, Shao M, et al. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans[J]. Q J Nucl Med Mol Imaging, 2015, 59(2): 220−227. [19] Elboga U, Karaoglan H, Sahin E, et al. F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience[J]. Eur Rev Med Pharmacol Sci, 2015, 19(3): 396−401. [20] Choi SJ, Jung KP, Lee SS, et al. Clinical usefulness of F-18 FDG PET/CT in Papillary thyroid cancer with negative radioiodine scan and elevated thyroglobulin level or positive anti-thyroglobulin antibody[J]. Nucl Med Mol Imaging, 2016, 50(2): 130−136. DOI: 10.1007/s13139-015-0378-5. [21] 薛明媚, 刘保平, 谢新立, 等. 18F-FDG PET/CT检测Tg阳性而131I-诊断剂量全身显像阴性分化型甲状腺癌患者复发和转移[J]. 中国医学影像技术, 2016, 32(2): 218−222. DOI: 10.13929/j.1003-3289.2016.02.014.
Xue MM, Li BP, Xie XL, et al. 18F-FDG PET/CT in detection of recurrence or metastatic of DTC patients with elevated serum Tg levels and negative 131I-Dx-WBS[J]. Chin J Med Imaging Technol, 2016, 32(2): 218−222. DOI: 10.13929/j.1003-3289.2016.02.014.[22] 程旭, 李永军, 许昕丹, 等. 18F-FDG PET/CT检测131I-治疗剂量全身显像阴性而甲状腺球蛋白阳性分化型甲状腺癌复发和转移[J]. 中国医学影像技术, 2018, 34(6): 855−859. DOI: 10.13929/j.1003-3289.201711001.
Cheng X, Li YJ, Xu XD, et al. 18F-FDG PET/CT in detection of recurrence and/or metastasis of differentiated thyroid carcinoma in patients with elevated serum thyroglobulin levels and negative 131I post-therapy whole body scan[J]. Chin J Med Imaging Technol, 2018, 34(6): 855−859. DOI: 10.13929/j.1003-3289.201711001.[23] Piccardo A, Trimboli P, Puntoni M, et al. Role of 18F-choline positron emission tomography/computed tomography to detect structural relapse in high-risk differentiated thyroid cancer patients[J]. Thyroid, 2019, 29(4): 549−556. DOI: 10.1089/thy.2018.0552. [24] Albano D, Tulchinsky M, Dondi F, et al. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma[J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 461−468. DOI: 10.1007/s00259-020-04992-8. [25] Almeida LS, Araújo ML, Santos AO, et al. Head-to-head comparison of F-18 FDG PET/CT in radioidine refractory thyroid cancer patients with elevated versus suppressed TSH levels a pilot study[J/OL]. Heliyon, 2020, 6(3): e03450[2021-03-16]. https://www.sciencedirect.com/science/article/pii/S2405844020302954. DOI: 10.1016/j.heliyon.2020.e03450. [26] Giovanella L, Deandreis D, Vrachimis A, et al. Molecular imaging and theragnostics of thyroid cancers[J/OL]. Cancers (Basel), 2022, 14(5): 1272[2022-04-01]. https://www.mdpi.com/2072-6694/14/5/1272. DOI: 10.3390/cancers14051272. [27] Zampella E, Klain M, Pace L, et al. PET/CT in the management of differentiated thyroid cancer[J/OL]. Diagn Interv Imaging, 2021, 102(9): 515−523[2022-04-01]. https://www.sciencedirect.com/science/article/abs/pii/S2211568421000851?via%3Dihub. DOI: 10.1016/j.diii.2021.04.004. [28] Lodi Rizzini E, Repaci A, Tabacchi E, et al. Impact of 18F-FDG PET/CT on clinical management of suspected radio-iodine refractory differentiated thyroid cancer (RAI-R-DTC)[J/OL]. Diagnostics (Basel), 2021, 11(8): 1430[2022-04-01]. https://www.mdpi.com/2075-4418/11/8/1430. DOI: 10.3390/diagnostics11081430. [29] Ferrari C, Santo G, Ruta R, et al. Early predictive response to multi-tyrosine kinase inhibitors in advanced refractory radioactive-iodine differentiated thyroid cancer: a new challenge for [18F]FDG PET/CT[J/OL]. Diagnostics (Basel), 2021, 11(8): 1417[2022-04-01]. https://www.mdpi.com/2075-4418/11/8/1417. DOI: 10.3390/diagnostics11081417. [30] Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma[J]. Eur J Nucl Med, 1998, 25(3): 242−246. DOI: 10.1007/s002590050223. [31] 邹仁健, 傅宏亮, 吴靖川, 等. 分化型甲状腺癌131I治疗中多种核素显像的联合应用[J]. 上海交通大学学报(医学版), 2010, 30(3): 256−258. DOI: 10.3969/j.issn.1674-8115.2010.03.003.
Zou RJ, Fu HL, Wu JC, et al. Clinical value of combination of multiple radionuclide imaging methods in 131I therapy for differentiated thyroid carcinoma[J]. J Shanghai Jiaotong Univ: Med Sci, 2010, 30(3): 256−258. DOI: 10.3969/j.issn.1674-8115.2010.03.003.[32] Ma C, Xie JW, Lou YH, et al. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis[J]. Eur J Endocrinol, 2010, 163(2): 177−183. DOI: 10.1530/EJE-10-0256.